Addition Therapeutics is on a mission to fulfill the transformative promise of genomic medicine for people impacted by both chronic and rare diseases. Leveraging our breakthrough all-RNA, non-viral, LNP-based PRINT™ platform, we are overcoming the limitations of existing genetic medicine modalities to develop safer, durable, one-time therapies. Bolstered by our team of top-tier scientists and engineers, we are advancing a robust pipeline of PRINTed therapeutics that have the potential to fundamentally redefine how chronic and rare diseases are treated. Our investor syndicate includes SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, the Gates Foundation, and BEVC.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/17/25 | $100,000,000 |
Abingworth BEVC Gates Foundation Osage University Partners Pivotal Life Sciences SR One | undisclosed |
